Arcus Biosciences Business Summary

Arcus Biosciences, Inc. (RCUS) is a clinical-stage biopharmaceutical company that generates revenue primarily through strategic collaborations, licensing agreements, and milestone payments, most notably via its multi-year oncology partnership with Gilead Sciences. The company operates through a single business segment focused on the discovery, development, and commercialization of next-generation cancer immunotherapies and treatments for inflammatory diseases. Its high-density pipeline is centered on the ATP-adenosine pathway and includes late-stage candidates such as casdatifan (a HIF-2α inhibitor), quemliclustat (a CD73 inhibitor), and domvanalimab (an anti-TIGIT antibody). Arcus competes directly with oncology giants like Merck & Co., Bristol Myers Squibb, Roche, and AstraZeneca, positioning itself as a specialized challenger that leverages novel combination therapies to target immunosuppressive mechanisms within the tumor microenvironment. The company was co-founded in 2015 by CEO Terry Rosen, Ph.D., and President Juan Jaen, Ph.D., both of whom previously co-founded Flexus Biosciences, which was acquired by Bristol Myers Squibb for $1.25 billion. The leadership team includes Chief Operating Officer Jennifer Jarrett, Chief Medical Officer Richard Markus, M.D., Ph.D., and Chief Scientific Officer Jonathan Yingling, Ph.D., all of whom bring extensive pedigree from firms such as Amgen, Medivation, and Uber. Arcus is backed by significant institutional investment, with Gilead Sciences holding an approximate 33% equity stake and maintaining representation on the Board of Directors through executives like Gilead CMO Dietmar Berger. Other notable board members and early investors include representatives from GV (formerly Google Ventures), Taiho Ventures, and former executives from Jazz Pharmaceuticals.